Phase 3 Trial Demonstrates Cannabis Extract VER-01 Significantly Reduces Chronic Low Back Pain
Key Insights
A multicenter phase 3 trial of 820 adults showed that full-spectrum cannabis extract VER-01 achieved a significant 1.9-point reduction in pain intensity compared to 1.4 points with placebo over 12 weeks.
The study found 54.1% of patients receiving VER-01 achieved at least 30% pain reduction versus 39.5% in the placebo group, with particularly strong efficacy in neuropathic pain (search) cases.
The cannabis extract demonstrated a favorable safety profile with no signs of drug dependence or withdrawal, offering a potential non-addictive alternative to opioids (search) for chronic low back pain (search) management.
A phase 3 randomized controlled trial has demonstrated that a standardized full-spectrum cannabis extract significantly reduces pain intensity in patients with chronic low back pain (search), potentially offering a non-addictive alternative to current treatments limited by addiction risks and adverse effects. The study, led by Matthias Karst from Hannover Medical School and published in Nature Medicine, represents a major advancement in addressing what researchers describe as the primary global cause of disability and reduced quality of life.
Trial Design and Patient Population
The multicenter, double-blind, placebo-controlled trial enrolled 820 adults across 66 outpatient and hospital sites in Germany and Austria. Participants were randomized to receive either VER-01, a full-spectrum cannabis extract, or placebo during a 12-week treatment phase. The study excluded individuals with identifiable treatable somatic causes or substance use disorders to ensure a focused patient population.
The primary endpoint measured changes in mean morning pain intensity using the 11-point Numeric Rating Scale (NRS). Secondary outcomes included Neuropathic Pain (search) Symptom Inventory (NPSI) scores in patients with neuropathic pain components. Statistical analyses incorporated covariance modeling and multiple imputation methods to strengthen the robustness of results.
Significant Pain Reduction Outcomes
The trial demonstrated notable analgesic effects, with VER-01 achieving a mean pain decrease of 1.9 points on the 11-point scale compared to a 1.4-point reduction in the control group. This difference represents clinically meaningful pain relief that exceeded placebo effects.
Responder rates further highlighted the treatment's efficacy, with 54.1% of VER-01 participants achieving at least a 30% reduction in pain intensity, significantly higher than the 39.5% response rate observed in the placebo arm. This substantial difference in responder rates indicates that more than half of patients experienced clinically relevant pain improvement.
Enhanced Neuropathic Pain Relief
For patients presenting with nerve-related symptoms, the cannabis extract demonstrated particularly strong efficacy. The research recorded a substantial NPSI total score drop of 14.4 points in the VER-01 group, doubling the relief reported by patients receiving placebo. This finding suggests the extract may be especially beneficial for chronic low back pain (search) cases with neuropathic components.
Quality of Life Improvements
Clinical benefits extended beyond pain reduction, with participants experiencing comprehensive quality of life enhancements. The study reported sleep quality improvements of 2.2 points alongside significant advancements in physical health component summary scores. These broader improvements indicate that VER-01's therapeutic effects encompass multiple aspects of patient wellbeing affected by chronic pain conditions.
Safety Profile and Tolerability
The research confirmed that VER-01 was well-tolerated with no signals of drug dependence or withdrawal, addressing critical concerns about addiction potential that limit current opioid-based treatments. While adverse events such as dizziness occurred more frequently in the treatment group, these effects were primarily mild and transient.
The study authors noted that medical professionals may find it helpful to inform patients that mild, passing side effects such as lightheadedness or fatigue might occur during the first few weeks of dose titration to encourage continued participation in the treatment plan.
Clinical Implications and Future Directions
The results position the standardized cannabis extract as a safe and potent treatment option for persistent back pain, offering a potential solution to the critical clinical gap created by the limitations of NSAIDs (search) and the ongoing opioid addiction crisis. The combination of significant pain reduction, high responder rates, and favorable safety profile suggests VER-01 could serve as a nonaddictive, effective long-term therapeutic option.
While the trial did not specifically measure changes in cognitive ability or directly compare the extract to traditional opioid therapies, the researchers noted an opportunity for subsequent investigations to determine if these beneficial outcomes can be replicated across a broader range of chronic pain syndromes.